MA29675B1 - Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione - Google Patents
Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedioneInfo
- Publication number
- MA29675B1 MA29675B1 MA30295A MA30295A MA29675B1 MA 29675 B1 MA29675 B1 MA 29675B1 MA 30295 A MA30295 A MA 30295A MA 30295 A MA30295 A MA 30295A MA 29675 B1 MA29675 B1 MA 29675B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical formulation
- formulation containing
- thiazolidinedione derivative
- novel pharmaceutical
- containing biguanide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne et décrit une forme posologique pharmaceutique comprenant un composant à libération contrôlée contenant un médicament antihyperglycémique en combinaison avec un deuxième composant contenant un dérivé de thiazolidinedione.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/093,742 US9060941B2 (en) | 2002-09-20 | 2005-03-30 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29675B1 true MA29675B1 (fr) | 2008-08-01 |
Family
ID=37073782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30295A MA29675B1 (fr) | 2005-03-30 | 2007-10-11 | Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione |
Country Status (25)
Country | Link |
---|---|
US (1) | US9060941B2 (fr) |
EP (1) | EP1863445B1 (fr) |
JP (2) | JP5827781B2 (fr) |
KR (1) | KR101401412B1 (fr) |
CN (1) | CN101222912B (fr) |
AR (1) | AR054238A1 (fr) |
AU (1) | AU2006232993B2 (fr) |
BR (1) | BRPI0609550A2 (fr) |
CA (1) | CA2601501C (fr) |
CR (1) | CR9355A (fr) |
EA (1) | EA015244B1 (fr) |
ES (1) | ES2573321T3 (fr) |
GE (1) | GEP20104936B (fr) |
HK (1) | HK1114337A1 (fr) |
IL (1) | IL186308A (fr) |
MA (1) | MA29675B1 (fr) |
MX (1) | MX2007011824A (fr) |
NO (1) | NO20075427L (fr) |
NZ (1) | NZ561124A (fr) |
PE (1) | PE20061389A1 (fr) |
SG (1) | SG160415A1 (fr) |
TW (1) | TWI344375B (fr) |
UA (1) | UA91852C2 (fr) |
WO (1) | WO2006107528A1 (fr) |
ZA (1) | ZA200707137B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
WO2003105809A1 (fr) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
WO2005117591A2 (fr) * | 2004-05-28 | 2005-12-15 | Andrx Labs Llc | Nouvelle formulation pharmaceutique contenant un biguanide et un antagoniste d'angiotensine |
US20080026054A1 (en) * | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
MX2010010280A (es) * | 2008-03-21 | 2010-12-15 | Mylan Pharmaceuticals Inc | Formulacion de liberacion prolongada que contiene una cera. |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
US20120093878A1 (en) * | 2010-07-30 | 2012-04-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a thiazolidinedione |
US20130251795A1 (en) * | 2010-07-30 | 2013-09-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent |
CN101912375A (zh) * | 2010-08-26 | 2010-12-15 | 冯岩 | 一种二甲双胍控释片 |
CN102727459A (zh) * | 2011-04-15 | 2012-10-17 | 江苏豪森医药集团有限公司 | 一种具有第一和第二活性药物的制剂 |
EA201490840A1 (ru) | 2011-10-21 | 2014-08-29 | Такеда Фармасьютикал Компани Лимитед | Препарат с замедленным высвобождением |
WO2014171542A1 (fr) * | 2013-04-19 | 2014-10-23 | 武田薬品工業株式会社 | Formulation de médicament à libération contrôlée |
EP3025707A1 (fr) * | 2014-11-27 | 2016-06-01 | Arven Ilac Sanayi Ve Ticaret A.S. | Comprimé multicouche comprenant de la metformine et du pioglitazone |
US20210290639A1 (en) * | 2018-08-02 | 2021-09-23 | Hospital Sant Joan De Deu | Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome |
GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4080472A (en) * | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4058122A (en) * | 1976-02-02 | 1977-11-15 | Alza Corporation | Osmotic system with laminated wall formed of different materials |
US4166800A (en) * | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
US4220648A (en) * | 1979-01-22 | 1980-09-02 | The Upjohn Company | Antidiabetic 1,2-dihydro-2-oxo-6-neopentyl-nicotinic acids |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
CA1266827A (fr) | 1984-06-20 | 1990-03-20 | Merck & Co., Inc. | Pompe osmotique a porosite controlee |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
GB8618811D0 (en) * | 1986-08-01 | 1986-09-10 | Approved Prescription Services | Sustained release ibuprofen formulation |
CH668187A5 (de) * | 1986-08-07 | 1988-12-15 | Ciba Geigy Ag | Therapeutisches system mit systemischer wirkung. |
FR2611500B1 (fr) | 1987-03-06 | 1990-05-04 | Lipha | Emploi de derives du biguanide dans la preparation de medicaments |
US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
US4857337A (en) * | 1988-05-24 | 1989-08-15 | American Home Products Corp. (Del) | Enteric coated aspirin tablets |
US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
DD295760A5 (de) * | 1989-01-31 | 1991-11-14 | Martin-Luther-Universitaet Halle Wittenberg,De | Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung |
HU205851B (en) | 1989-01-31 | 1992-07-28 | Int Pharma Agentur | Systhem of regulated release of the active components and process for producing it |
US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
US5900435A (en) | 1991-08-26 | 1999-05-04 | Pharmacia & Upjohn Company | Composition, food product and uses of 3-guanidinopropionic acid |
US5200194A (en) * | 1991-12-18 | 1993-04-06 | Alza Corporation | Oral osmotic device |
US5294770A (en) * | 1992-01-14 | 1994-03-15 | Alza Corporation | Laser tablet treatment system with dual access to tablet |
US5376771A (en) * | 1992-07-07 | 1994-12-27 | Merck & Co., Inc. | High speed process for preparing orifices in pharmaceutical dosage forms |
US5547683A (en) * | 1992-10-09 | 1996-08-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Method for producing microgranulated particle |
DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US5917052A (en) | 1994-09-28 | 1999-06-29 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
AUPM897594A0 (en) * | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
US5658474A (en) * | 1994-12-16 | 1997-08-19 | Alza Corporation | Method and apparatus for forming dispenser delivery ports |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
AU706628B2 (en) | 1995-07-03 | 1999-06-17 | Sankyo Company Limited | Treatment of arteriosclerosis and xanthoma |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
CA2290624C (fr) | 1997-06-06 | 2006-12-05 | John W. Shell | Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
ES2216335T3 (es) * | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
US5948440A (en) * | 1997-12-17 | 1999-09-07 | Ranbaxy Laboratories Limited | Modified release matrix formulation of cefaclor and cephalexin |
CN1203846C (zh) | 1998-03-19 | 2005-06-01 | 布里斯托尔-迈尔斯斯奎布公司 | 高溶解性药物的双相控释递送系统和方法 |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
AU3536299A (en) | 1998-04-29 | 1999-11-16 | Sumitomo Pharmaceuticals Company, Limited | Oral formulation comprising biguanide and an organic acid |
US6191162B1 (en) * | 1998-05-28 | 2001-02-20 | Medical Research Institute | Method of reducing serum glucose levels |
DE69929996T2 (de) * | 1998-06-30 | 2006-11-16 | Takeda Pharmaceutical Co. Ltd. | Pharmazeutisches mittel zur behandlung von diabetes |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
AU768994B2 (en) | 1998-11-12 | 2004-01-15 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
DK1180020T4 (da) | 1999-05-27 | 2009-10-05 | Acusphere Inc | Poröse lægemiddelmatrixer og fremgangsmåder til fremstilling deraf |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
JP2003514011A (ja) * | 1999-11-16 | 2003-04-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物 |
PT1239830E (pt) * | 1999-12-16 | 2005-05-31 | Alza Corp | Formas de dosagem com uma camada barreira para ablacao por laserc |
BR0007360A (pt) | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Composição de liberação controlada |
EP1239839A2 (fr) | 1999-12-23 | 2002-09-18 | Pfizer Products Inc. | Forme de dosage d'un medicament stratifie entraine par un hydrogel |
AR026148A1 (es) * | 2000-01-21 | 2003-01-29 | Osmotica Argentina S A | Dispositivo osmotico con pasaje preformado que aumenta de tamano |
SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
US6296874B1 (en) * | 2000-05-01 | 2001-10-02 | Aeropharm Technology Incorporated | Core formulation comprising troglitazone and abiguanide |
US6403121B1 (en) * | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
US6451342B2 (en) * | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
US6524621B2 (en) * | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
DE10025946A1 (de) * | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination |
US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
EP1322158B1 (fr) | 2000-10-02 | 2012-08-08 | USV Ltd. | Compositions pharmaceutiques a liberation prolongee contenant de la metformine, procedes de production de ces dernieres |
US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
US6790459B1 (en) * | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
KR20030076634A (ko) | 2001-01-30 | 2003-09-26 | 데이진 가부시키가이샤 | 의약 조성물 |
JP4848558B2 (ja) | 2001-05-08 | 2011-12-28 | トーアエイヨー株式会社 | 塩酸メトホルミン含有速放性錠剤 |
US6838093B2 (en) * | 2001-06-01 | 2005-01-04 | Shire Laboratories, Inc. | System for osmotic delivery of pharmaceutically active agents |
US20030021841A1 (en) | 2001-07-02 | 2003-01-30 | Matharu Amol Singh | Pharmaceutical composition |
US6703045B2 (en) * | 2001-08-21 | 2004-03-09 | Council Of Scientific & Industrial Research | Composition and method for maintaining blood glucose level |
US20030118649A1 (en) * | 2001-10-04 | 2003-06-26 | Jinming Gao | Drug delivery devices and methods |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US8329217B2 (en) * | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
ITFI20010230A1 (it) | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
US20030118647A1 (en) * | 2001-12-04 | 2003-06-26 | Pawan Seth | Extended release tablet of metformin |
US20030224046A1 (en) * | 2002-06-03 | 2003-12-04 | Vinay Rao | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent |
WO2003105809A1 (fr) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes |
US20060286168A1 (en) | 2002-07-11 | 2006-12-21 | Masahiko Koike | Process for producing coated preparation |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) * | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
KR20120034211A (ko) | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
IN192749B (fr) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
EP1588708A4 (fr) * | 2003-01-29 | 2006-03-01 | Takeda Pharmaceutical | Procede pour realiser une preparation enrobee |
TWI350751B (en) | 2003-12-19 | 2011-10-21 | Omega Bio Pharma Ip3 Ltd | Pharmaceutical compositions for treating diabetes |
EP1748776A1 (fr) | 2004-05-03 | 2007-02-07 | Duke University | Compositions influant sur la perte de poids |
CN1327840C (zh) | 2004-06-08 | 2007-07-25 | 天津药物研究院 | 一种药物组合物及其在制备用于治疗糖尿病中的应用 |
-
2005
- 2005-03-30 US US11/093,742 patent/US9060941B2/en active Active
-
2006
- 2006-03-13 WO PCT/US2006/009082 patent/WO2006107528A1/fr active Application Filing
- 2006-03-13 EP EP06738170.7A patent/EP1863445B1/fr active Active
- 2006-03-13 AU AU2006232993A patent/AU2006232993B2/en not_active Ceased
- 2006-03-13 MX MX2007011824A patent/MX2007011824A/es active IP Right Grant
- 2006-03-13 ES ES06738170.7T patent/ES2573321T3/es active Active
- 2006-03-13 BR BRPI0609550-0A patent/BRPI0609550A2/pt not_active IP Right Cessation
- 2006-03-13 SG SG201001858-8A patent/SG160415A1/en unknown
- 2006-03-13 JP JP2008504090A patent/JP5827781B2/ja not_active Expired - Fee Related
- 2006-03-13 CA CA2601501A patent/CA2601501C/fr not_active Expired - Fee Related
- 2006-03-13 KR KR1020077021377A patent/KR101401412B1/ko not_active IP Right Cessation
- 2006-03-13 GE GEAP200610344A patent/GEP20104936B/en unknown
- 2006-03-13 NZ NZ561124A patent/NZ561124A/en not_active IP Right Cessation
- 2006-03-13 CN CN2006800097636A patent/CN101222912B/zh not_active Expired - Fee Related
- 2006-03-13 EA EA200702116A patent/EA015244B1/ru not_active IP Right Cessation
- 2006-03-13 UA UAA200712007A patent/UA91852C2/ru unknown
- 2006-03-15 AR AR20060100990A patent/AR054238A1/es unknown
- 2006-03-22 TW TW095109953A patent/TWI344375B/zh not_active IP Right Cessation
- 2006-03-30 PE PE2006000354A patent/PE20061389A1/es not_active Application Discontinuation
-
2007
- 2007-08-23 ZA ZA2007/07137A patent/ZA200707137B/en unknown
- 2007-08-29 CR CR9355A patent/CR9355A/es unknown
- 2007-09-25 IL IL186308A patent/IL186308A/en not_active IP Right Cessation
- 2007-10-11 MA MA30295A patent/MA29675B1/fr unknown
- 2007-10-25 NO NO20075427A patent/NO20075427L/no not_active Application Discontinuation
-
2008
- 2008-09-08 HK HK08109948.6A patent/HK1114337A1/xx not_active IP Right Cessation
-
2013
- 2013-06-19 JP JP2013129075A patent/JP2013209426A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29675B1 (fr) | Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione | |
ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
NO20053076D0 (no) | Farmasoytisk formulering med en uloselig aktiv forbindelse. | |
MA30504B1 (fr) | Compositions pharmaceutiques stabilisees comprenant de la fesoterodine | |
MA30085B1 (fr) | Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione | |
MA28155A1 (fr) | Composition pharmaceutique | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
BRPI0620229A8 (pt) | formulação | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
CR10091A (es) | Compuestos orgánicos | |
MY149306A (en) | Solid preparation containing an insulin sensitizer | |
DE602004011398D1 (de) | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 | |
ATE549016T1 (de) | Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe | |
NO20064808L (no) | Orale matrixformuleringer med licarbazepin | |
CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
FR2871695B1 (fr) | Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises | |
PA8691901A1 (es) | Composicion farmaceutica solida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph | |
NO20064783L (no) | Opplosningstabeletter med licarbazepin | |
MA30815B1 (fr) | Medicament combine | |
WO2007009691A3 (fr) | Combinaison de substances active s | |
CL2007002315A1 (es) | Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable. |